Erin L Winstanley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8890439/publications.pdf

Version: 2024-02-01

54 1,905 22 42 papers citations h-index g-index

55 55 2925 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	A Systematic Review of Community Opioid Overdose Prevention and Naloxone Distribution Programs. Journal of Addiction Medicine, 2014, 8, 153-163.	2.6	352
2	The association of self-reported neighborhood disorganization and social capital with adolescent alcohol and drug use, dependence, and access to treatment. Drug and Alcohol Dependence, 2008, 92, 173-182.	3.2	148
3	Emergency Department Prescription Opioids as an Initial Exposure Preceding Addiction. Annals of Emergency Medicine, 2016, 68, 202-208.	0.6	145
4	Using e-technologies in clinical trials. Contemporary Clinical Trials, 2015, 45, 41-54.	1.8	124
5	Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary caseâ€series and feasibility. Addiction, 2010, 105, 1669-1676.	3.3	80
6	Moving Beyond Misuse and Diversion: The Urgent Need to Consider the Role of latrogenic Addiction in the Current Opioid Epidemic. American Journal of Public Health, 2014, 104, 2023-2029.	2.7	79
7	Mandatory review of a prescription drug monitoring program and impact on opioid and benzodiazepine dispensing. Drug and Alcohol Dependence, 2018, 188, 169-174.	3.2	72
8	Duloxetine in the treatment of binge eating disorder with depressive disorders: A placeboâ€controlled trial. International Journal of Eating Disorders, 2012, 45, 281-289.	4.0	65
9	A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. International Clinical Psychopharmacology, 2011, 26, 48-53.	1.7	61
10	The Impact of the Opioid Epidemic on Children and Adolescents. Clinical Therapeutics, 2019, 41, 1655-1662.	2.5	57
11	Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or pain. Journal of Addictive Diseases, 2016, 35, 42-51.	1.3	55
12	Strategies and policies to address the opioid epidemic: A case study of Ohio. Journal of the American Pharmacists Association: JAPhA, 2017, 57, S148-S153.	1.5	54
13	Barriers to Implementation of Opioid Overdose Prevention Programs in Ohio. Substance Abuse, 2016, 37, 42-46.	2.3	53
14	Acamprosate in the treatment of binge eating disorder: A placeboâ€controlled trial. International Journal of Eating Disorders, 2011, 44, 81-90.	4.0	50
15	Topiramate for cocaine dependence during methadone maintenance treatment: A randomized controlled trial. Drug and Alcohol Dependence, 2014, 140, 92-100.	3.2	43
16	A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. Journal of Substance Abuse Treatment, 2011, 40, 255-264.	2.8	40
17	Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania. Journal of Affective Disorders, 2010, 124, 157-163.	4.1	31
18	The Bell Tolls for Thee & Thine: Compassion Fatigue & The Overdose Epidemic. International Journal of Drug Policy, 2020, 85, 102796.	3.3	29

#	Article	IF	Citations
19	A Randomized, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain. Journal of Clinical Psychopharmacology, 2012, 32, 165-172.	1.4	28
20	Using digital technologies in clinical trials: Current and future applications. Contemporary Clinical Trials, 2021, 100, 106219.	1.8	28
21	Sodium oxybate in the treatment of binge eating disorder: An openâ€label, prospective study. International Journal of Eating Disorders, 2011, 44, 262-268.	4.0	27
22	West Virginia's model of buprenorphine expansion: Preliminary results. Journal of Substance Abuse Treatment, 2020, 108, 40-47.	2.8	27
23	Adolescent Substance Abuse and Mental Health: Problem Co-Occurrence and Access to Services. Journal of Child and Adolescent Substance Abuse, 2012, 21, 310-322.	0.5	24
24	Inpatient Experiences with MyChart Bedside. Telemedicine Journal and E-Health, 2017, 23, 691-693.	2.8	24
25	High prevalence of co-occurring substance use in individuals with opioid use disorder. Addictive Behaviors, 2021, 114, 106752.	3.0	19
26	The potential impact of recruitment method on sample characteristics and treatment outcomes in a psychosocial trial for women with co-occurring substance use disorder and PTSD. Drug and Alcohol Dependence, 2012, 120, 225-228.	3.2	17
27	Something to despair: Gender differences in adverse childhood experiences among rural patients. Journal of Substance Abuse Treatment, 2020, 116, 108056.	2.8	16
28	Neurocognitive impairments and brain abnormalities resulting from opioid-related overdoses: A systematic review. Drug and Alcohol Dependence, 2021, 226, 108838.	3.2	15
29	Prescription Drug Abuse as a Public Health Problem in Ohio: A Case Report. Public Health Nursing, 2012, 29, 553-562.	1.5	13
30	The development and feasibility of a pharmacy-delivered opioid intervention in the emergency department. Journal of the American Pharmacists Association: JAPhA, 2017, 57, S87-S91.	1.5	13
31	Long-term treatment retention in West Virginia's comprehensive opioid addiction treatment (COAT) program. Journal of the Neurological Sciences, 2020, 411, 116712.	0.6	13
32	Drug abuse and HIV/AIDS: international research lessons and imperatives. Drug and Alcohol Dependence, 2006, 82, S1-S5.	3.2	12
33	Emergency Physicians' Perception of Barriers and Facilitators for Adopting an Opioid Prescribing Guideline in Ohio: A Qualitative Interview Study. Journal of Emergency Medicine, 2019, 56, 15-22.	0.7	10
34	Concurrent Alcohol and Opioid Use Among Harm Reduction Clients. Addictive Behaviors, 2020, 100, 106027.	3.0	10
35	Hepatitis C virus infection and polysubstance use among young adult people who inject drugs in a rural county of New Mexico. Drug and Alcohol Dependence, 2021, 220, 108527.	3.2	10
36	Response to "Quality Assessment Errors and Study Misclassification Threaten Systematic Review Validity. Journal of Addiction Medicine, 2015, 9, 503-504.	2.6	9

#	Article	IF	CITATIONS
37	The world of drinking: national alcohol control experiences in 18 countries. Addiction, 2008, 103, 721-725.	3.3	8
38	Development and Implementation of an Opioid Overdose Prevention Program Within a Preexisting Substance Use Disorders Treatment Center. Journal of Addiction Medicine, 2014, 8, 164-169.	2.6	5
39	Assessing Fidelity of a Communityâ€Based Opioid Overdose Prevention Program: Modification of the Fidelity Checklist. Journal of Nursing Scholarship, 2016, 48, 371-377.	2.4	5
40	Tangledâ€up and blue: releasing the regulatory chokehold on takeâ€home naloxone. Addiction, 2016, 111, 583-584.	3.3	4
41	Polysubstance Use, Mood Disorders, and Chronic Conditions With Anxiety in Opioid Patients. Western Journal of Nursing Research, 2022, 44, 1088-1099.	1.4	4
42	Distinguishing clinical factors associated with unintentional overdose, suicidal ideation, and attempted suicide among opioid use disorder in-patients. Journal of Psychiatric Research, 2022, 153, 245-253.	3.1	4
43	Improving Treatment for Opioid Dependence: A Perspective From the Ohio Valley Node of the NIDA Clinical Trials Network. Progress in Community Health Partnerships: Research, Education, and Action, 2014, 8, 99-107.	0.3	3
44	Statewide cross-sectional survey of emergency departments' adoption and implementation of the Ohio opioid prescribing guidelines and opioid prescribing practices. BMJ Open, 2018, 8, e020477.	1.9	3
45	The Promise of Technology-Based Services for Addiction Treatment Clients Residing in Nonurban Areas. Journal of Studies on Alcohol and Drugs, 2018, 79, 503-504.	1.0	3
46	Feasibility and acceptability of safety screening among patients receiving addiction treatment. Journal of Substance Abuse Treatment, 2020, 117, 108092.	2.8	3
47	Experiences and opinions of health professional students participating in an opioid use disorder educational event. Mental Health Clinician, 2020, 10, 49-54.	1.0	3
48	Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy. Journal of the American Pharmacists Association: JAPhA, 2020, 60, e205-e214.	1.5	2
49	Assessment of Gabapentin Misuse using Prescription Drug Monitoring Program Data. Substance Abuse, 2021, 42, 454-459.	2.3	2
50	The impact of rural classification systems on a comparison of risky drug-related behaviors in Kentucky and Ohio counties. Journal of Human Behavior in the Social Environment, 2019, 29, 301-307.	1.9	1
51	Rapid Transition of Individual and Group-based Behavioral Outpatient Visits to Telepsychiatry in Response to COVID-19. Journal of Addiction Medicine, 2021, 15, 263-265.	2.6	1
52	Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale. Journal of Affective Disorders, 2022, 297, 148-155.	4.1	1
53	Implementation of an inpatient opioid overdose prevention program. Addictive Behaviors, 2016, 53, 141-145.	3.0	0
54	OD: Naloxone and the Politics of Overdose. NancyCampbellBoston, MA, USA: MIT Press; 2020 ISBN: 9780262043663. Addiction, 2021, 116, 209-210.	3.3	0